| Articolul precedent |
| Articolul urmator |
 |
 377 1 |
| Ultima descărcare din IBN: 2022-04-04 11:03 |
 SM ISO690:2012CEPRAGA, Victoria, PALEGA, Daniela, MUNTEANU, Ana, LUPU, Victoria, SELEVESTRU, Rodica, PALII, Ina, ŞCIUCA, Svetlana. Evaluation of ecocardiographical indicators in pulmonary hypertension in children with bronchiectasis. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 363. ISBN 978-9975-82-223-7 (PDF).. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | ||||||
|
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | ||||||
|
||||||
| Pag. 363-363 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
Background. Arterial hypoxemia is the leading cause of secondary pulmonary hypertension (HP) in patients with bronchopulmonary disease, especially in those with cystic fibrosis (CF). Objective of the study. Evaluation of secondary pulmonary hypertension in children with bronchiectasis from chronic bronchopulmonary diseases Material and Methods. The study included 37 children with chronic bronchopulmonary disease:22 children (59.5%:95%CI 42.1-75.2) with CF and 15(40.5%: 95% CI 24.8-57.9 ) with other bronchopulmonarydiseases.Patients were evaluated by M 2D color Doppler EcoCG with assessment of pulmonary arterial systolic pressure (PSAP), tricuspid valve insufficiency (IVT) and chest computed tomography (CT). Results. The average age of children with CF-7.72±0.92 years(variations 0.5–15.5 years) and 9.69±1.42 years (1.5–17 years)-control group; F state 1.57,P>0.05. The PSAP value is increased in children with FC-33.5±1.6 mmHg(minimum-22 mmHg, maximum-50 mmHg), compared to children in the control group-28.8±1.7 mmHg(variations 22–47 mmHg);F state 3.9,P>0.05.IVT in CF was found in 19 children(95%:95%CI 75.1-99.9) and in all children of the control group, χ2=0.6, p>0.05.Children with CF had varicose(36.4%) and cylindrical(40.9%) bronchiectasis, compared to those in the control group in which traction(46.7%), cylindrical(33.3%) and more rarely predominated varicose bronchiectasis. Conclusion. PSAP is increased in children with CF, who have more severe lung damage due to the presence of extensive bronchiectasis compared to patients with non-CF bronchiectasis. |
||||||
| Cuvinte-cheie pulmonaryhypertension, cysticfibrosis, children, hipertensiunea pulmonară, Fibroza chistică, copii |
||||||
|
DataCite XML Export
<?xml version='1.0' encoding='utf-8'?> <resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'> <creators> <creator> <creatorName>Cepraga, V.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Palega, D.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Munteanu, A.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Lupu, V.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Selevestru, R.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Palii, I.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Şciuca, S.S.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> </creators> <titles> <title xml:lang='en,ro'>Evaluation of ecocardiographical indicators in pulmonary hypertension in children with bronchiectasis</title> </titles> <publisher>Instrumentul Bibliometric National</publisher> <publicationYear>2021</publicationYear> <relatedIdentifier relatedIdentifierType='ISBN' relationType='IsPartOf'>978-9975-82-223-7 (PDF).</relatedIdentifier> <subjects> <subject>pulmonaryhypertension</subject> <subject>cysticfibrosis</subject> <subject>children</subject> <subject>hipertensiunea pulmonară</subject> <subject>Fibroza chistică</subject> <subject>copii</subject> </subjects> <dates> <date dateType='Issued'>2021</date> </dates> <resourceType resourceTypeGeneral='Text'>Conference Paper</resourceType> <descriptions> <description xml:lang='en' descriptionType='Abstract'><p>Background. Arterial hypoxemia is the leading cause of secondary pulmonary hypertension (HP) in patients with bronchopulmonary disease, especially in those with cystic fibrosis (CF). Objective of the study. Evaluation of secondary pulmonary hypertension in children with bronchiectasis from chronic bronchopulmonary diseases Material and Methods. The study included 37 children with chronic bronchopulmonary disease:22 children (59.5%:95%CI 42.1-75.2) with CF and 15(40.5%: 95% CI 24.8-57.9 ) with other bronchopulmonarydiseases.Patients were evaluated by M 2D color Doppler EcoCG with assessment of pulmonary arterial systolic pressure (PSAP), tricuspid valve insufficiency (IVT) and chest computed tomography (CT). Results. The average age of children with CF-7.72±0.92 years(variations 0.5–15.5 years) and 9.69±1.42 years (1.5–17 years)-control group; F state 1.57,P>0.05. The PSAP value is increased in children with FC-33.5±1.6 mmHg(minimum-22 mmHg, maximum-50 mmHg), compared to children in the control group-28.8±1.7 mmHg(variations 22–47 mmHg);F state 3.9,P>0.05.IVT in CF was found in 19 children(95%:95%CI 75.1-99.9) and in all children of the control group, χ2=0.6, p>0.05.Children with CF had varicose(36.4%) and cylindrical(40.9%) bronchiectasis, compared to those in the control group in which traction(46.7%), cylindrical(33.3%) and more rarely predominated varicose bronchiectasis. Conclusion. PSAP is increased in children with CF, who have more severe lung damage due to the presence of extensive bronchiectasis compared to patients with non-CF bronchiectasis.</p></description> <description xml:lang='ro' descriptionType='Abstract'><p>Introducere. Hipoxemia arterială reprezintă cauza principală de apariție a hipertensiunii pulmonare secundare (HP) la pacienții cu maladii bronho-pulmonare, în special la cei cu fibroză chistică (FC). Scopul lucrării. Evaluarea hipertensiunii pulmonare secundare la copiii cu bronșiectazii din maladiile bronhopulmonare cronice. Material și metode. Studiul a inclus 37 de copii cu maladii cronice bronhopulmonare: 22 copii (59,5%:95%CI 42,1-75,2) cu FC și 15 copii (40,5%:95%CI 24,8-57,9) cu alte afecțiuni bronhopulmonare. Pacienții au fost evaluați prin EcoCG Doppler color regim M, 2D cu aprecierea presiunii sistolice în artera pulmonară (PSAP), a insuficienței valvei tricuspidiene (IVT) și computer tomografia (CT) toracelui. Rezultate. Vârsta medie a copiilor cu FC a constituit 7,72±0,92 ani (variații 0,5–15,5 ani) și 9,69±1,42 ani (1,5–17 ani) pentru lotul martor; F stat 1,57, P>0,05. Valoarea PSAP este majorată la copii cu FC – 33,5±1,6 mmHg (minim ‒ 22 mmHg, maxim – 50 mmHg), comparativ cu copiii din lotul martor – 28,8±1,7 mmHg (variații 22–47 mmHg); F stat 3,9, P>0,05. IVT în FC a fost constatată la 19 copii (95%: 95%CI 75,1-99,9) și la toți copiii lotului martor, χ2=0,6, P>0,05. Copiii cu FC imagistic prezentau bronșiectazii varicoase (36,4%) și cilindrice (40,9%), comparativ cu cei din lotul martor, la care predominau cele tracționale (46,7%), cilindrice (33,3%) și mai rar bronșiectazii varicoase. Concluzii. PSAP este majorată la copiii cu FC, care prezintă o afectare pulmonară mai severă, determinată de prezența bronșiectaziilor extinse, comparativ cu pacienții cu bronșiectazii non-FC.</p></description> </descriptions> <formats> <format>application/pdf</format> </formats> </resource>
|
|
|
